A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia.
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2013
At a glance
- Drugs Mavoglurant (Primary)
- Indications Drug-induced dyskinesia
- Focus Therapeutic Use
- 02 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Planned End Date changed from 1 Apr 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 09 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.